Navigation Links
KaloBios Pharmaceuticals Completes Initial Public Offering
Date:2/7/2013

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share. Gross proceeds from the offering were $70 million, and net proceeds were approximately $62 million, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by the company. Leerink Swann LLC acted as sole book-running manager for the offering. William Blair & Company, L.L.C. acted as the lead manager and Needham & Company LLC acted as co-manager for the offering.

A registration statement relating to these securities was declared effective by the SEC on January 31, 2013. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About KaloBios Pharmaceuticals

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.


'/>"/>
SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
3. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
4. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
5. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
6. Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
7. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
8. Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
9. Pharmaceuticals Announces $1.5 Million Second Closing in Private Placement
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):